Protein / target

Platelet-derived growth factor receptor beta

PDGFRBP09619Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
19
Approved medicines
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Platelet-derived growth factor beta-receptor activity

Primary system

Cardiovascular system

Strongest disease association

Basal ganglia calcification

Genetic evidence · score 0.87

Therapeutic maturity

Clinically validated target

19 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Approved Drug

Clinical development

19 approved · 26 in clinical development

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor

Subcellular location

Cell membraneCytoplasmic vesicleLysosome lumen
Domains and Gene Ontology detail (62)

Domains & features

Ig-like C2-type 1Ig-like C2-type 2Ig-like C2-type 3Ig-like C2-type 4Ig-like C2-type 5Protein kinase

Gene Ontology

  • Capical plasma membrane
  • Ccytoplasm
  • Ccytoplasmic vesicle
  • Cfocal adhesion
  • Clysosomal lumen
  • Cmembrane
  • Cnucleus
  • Cplasma membrane
  • Creceptor complex
  • FATP binding
  • Fenzyme binding
  • FGTPase activator activity

1106 aa · 124 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Kinase signallingUniProt · GOHaemostasisGOMetabolic enzyme activityGO
View supporting evidence

Kinase signalling

  • ·Tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and P…
  • ·protein kinase activity
  • ·protein kinase binding
  • ·protein tyrosine kinase activity

Haemostasis

  • ·platelet activating factor receptor activity
  • ·platelet-derived growth factor beta-receptor activity
  • ·platelet-derived growth factor binding
  • ·platelet-derived growth factor receptor activity

Metabolic enzyme activity

  • ·positive regulation of reactive oxygen species metabolic process
View underlying pathways (6)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

PDGFAPTPN11PDGFBPIK3R1PDGFDPLCG1GRB2SRCPDGFCEGFRPDGFRB

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

3

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Imatinib Mesylate
ApprovedInhibitor

Platelet-derived growth factor receptor beta inhibitor

Appears in clinical studies involving chronic myelogenous leukemia, BCR-ABL1 positive, myelodysplastic/myeloproliferative disease, gastrointestinal stromal tumor, dermatofibrosarcoma protuberans

Direct interaction with this protein · 1 of 4 recorded protein targets

sunitinib
ApprovedInhibitor

Platelet-derived growth factor receptor beta inhibitor

Appears in clinical studies involving gastrointestinal stromal tumor, renal cell carcinoma, gastrointestinal stromal tumor, neuroendocrine neoplasm

Direct interaction with this protein · 1 of 9 recorded protein targets — broad pharmacology

regorafenib
ApprovedInhibitor

Platelet-derived growth factor receptor inhibitor

Appears in clinical studies involving colorectal cancer, metastatic colorectal cancer, colorectal neoplasm, neoplasm

Acts on a complex — shared with PDGFRA · 1 of 18 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

Basal ganglia calcification0.87

Genetic · overall 0.78

infantile myofibromatosis0.87

Genetic literature · overall 0.75

bilateral striopallidodentate calcinosis0.85

Genetic · overall 0.77

myofibromatosis, infantile, 10.84

Genetic · overall 0.76

skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome0.81

Genetic · overall 0.74

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

chronic myelogenous leukemia, BCR-ABL1 positive0.99

Clinical · overall 0.65

gastrointestinal stromal tumor0.98

Clinical · overall 0.67

hepatocellular carcinoma0.97

Clinical · overall 0.67

acute myeloid leukemia0.91

Clinical · overall 0.65

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

acroosteolysis-keloid-like lesions-premature aging syndrome0.74

Genetic

Show all associations
Basal ganglia calcification0.78
bilateral striopallidodentate calcinosis0.77
myofibromatosis, infantile, 10.76
infantile myofibromatosis0.75
skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome0.74
acroosteolysis-keloid-like lesions-premature aging syndrome0.74
hepatocellular carcinoma0.67
gastrointestinal stromal tumor0.67
chronic myelogenous leukemia, BCR-ABL1 positive0.65
acute myeloid leukemia0.65

Open Targets ranks 3,132 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 45 total

NINTEDANIB ESYLATEApproval

idiopathic pulmonary fibrosis · systemic sclerosis · non-small cell lung carcinoma

TIVOZANIBApproval

renal cell carcinoma · neoplasm · renal cell adenocarcinoma

TANDUTINIBPhase 2

prostate cancer · clear cell renal carcinoma · grade III glioma

CEDIRANIBApproval

neoplasm · peritoneum cancer · colorectal cancer

BECAPLERMINApproval

Skin ulcer · diabetic foot · Skin ulcer

RINUCUMABPhase 2

age-related macular degeneration

FORETINIBPhase 2

breast cancer · gastric adenocarcinoma · renal cell carcinoma

SUNITINIBApproval

gastrointestinal stromal tumor · renal cell carcinoma · gastrointestinal stromal tumor

RG-1530Phase 1
MIDOSTAURINApproval

mast cell leukemia · mastocytosis · acute myeloid leukemia by FAB classification

Tractability

SM · Approved DrugSM · High-Quality LigandSM · Druggable FamilyAB · Advanced ClinicalAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule BinderOC · Approved Drug

Safety liabilities

heart disease

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

COMPLETED · via sunitinib · NCT00357318

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

infantile myofibromatosisWell supported
0.93
agreement 0.831.00
Genetic54%Somatic mutation37%Animal model7%Literature3%Genetic literaturedup

Open Targets aggregate 0.75 · 4 independent evidence families · 1 not counted as duplicate

myofibromatosis, infantile, 1Well supported
0.92
agreement 0.811.00
Genetic62%Somatic mutation38%Genetic literaturedup

Open Targets aggregate 0.76 · 2 independent evidence families · 1 not counted as duplicate

Basal ganglia calcificationWell supported
0.91
agreement 0.811.00
Genetic72%Animal model16%Somatic mutation11%Literature1%Genetic literaturedup

Open Targets aggregate 0.78 · 4 independent evidence families · 1 not counted as duplicate

bilateral striopallidodentate calcinosisWell supported
0.91
agreement 0.801.00
Genetic67%Animal model16%Somatic mutation11%Literature6%Genetic literaturedup

Open Targets aggregate 0.77 · 4 independent evidence families · 1 not counted as duplicate

acute myeloid leukemiaWell supported
0.84
agreement 0.750.94
Clinical53%Somatic mutation23%Genetic literature19%Literature5%

Open Targets aggregate 0.65 · 4 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

60

Recent activity around this target, drawn from one canonical event stream. Every item is reached through 3 drugs that target this protein, so each event is news about that drug rather than about the protein directly.

  1. Label change2026-07-13

    Label change: IMATINIB MESYLATE (NDA021588)

    fda · regulatory · fda · via Imatinib Mesylate

  2. Label change2026-01-14

    Label change: IMATINIB MESYLATE (NDA021588)

    fda · regulatory · fda · via Imatinib Mesylate

  3. New publication2025-01-06
    Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes.

    ESMO open · 2025 · 10 citations · Europe PMC · via regorafenib

  4. Label change2024-12-09

    Label change: IMATINIB (ANDA204644)

    fda · regulatory · fda · via Imatinib Mesylate

  5. New publication2024-06-04
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 69 citations · Europe PMC · via regorafenib

  6. New publication2024-05-03
    Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment.

    PLoS computational biology · 2024 · 10 citations · Europe PMC · via sunitinib

  7. Supplemental approval2024-03-01

    Supplemental approval: IMATINIB MESYLATE (NDA021588)

    fda · regulatory · fda · via Imatinib Mesylate

  8. New publication2024-02-27
    KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.

    Cell communication and signaling : CCS · 2024 · 28 citations · Europe PMC · via Imatinib Mesylate

  9. Label change2024-01-05

    Label change: IMATINIB (ANDA204644)

    fda · regulatory · fda · via Imatinib Mesylate

  10. Label change2024-01-05

    Label change: IMATINIB (ANDA204644)

    fda · regulatory · fda · via Imatinib Mesylate

  11. Label change2024-01-05

    Label change: IMATINIB (ANDA204644)

    fda · regulatory · fda · via Imatinib Mesylate

  12. Label change2024-01-05

    Label change: IMATINIB (ANDA204644)

    fda · regulatory · fda · via Imatinib Mesylate

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.